Krystal Biotech, Inc. (KRYS)
Pre-market:
| Previous close | 160.23 |
| Open | 163.55 |
| Bid | 160.55 x 100 |
| Ask | 161.17 x 100 |
| Day's range | 157.90 - 164.74 |
| 52-week range | 83.38 - 189.97 |
| Volume | |
| Avg. volume | 389,980 |
| Market cap | 4.594B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | 413.08 |
| EPS (TTM) | 0.39 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 188.50 |
GlobeNewswireKrystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
Net product revenue of $45.3 million in 1Q and $95.9 million since AugustFirst patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lungReceived Fast Track Designations for both inhaled and intratumoral KB707Strong balance sheet with $622.3 million in cash and investments PITTSBURGH, May 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business upd
ZacksWhy Krystal Biotech (KRYS) Might Surprise This Earnings Season
Krystal Biotech (KRYS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- GlobeNewswire
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data highlighting the potential of the Company’s HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington. Poster presentation details are as foll
